Summary

The cell culture market is projected to reach USD 58.42 billion by 2031 from an estimated USD 33.07 billion in 2026, at a CAGR of 12.1% during the forecast period of 2026 to 2031. The growth of this market can be attributed to increasing investment and funding for research in cell biology. The rising incidence of chronic diseases such as cancer is boosting the demand for advanced therapies such as tissue engineering and regenerative medicine. This trend is expected to drive the growth of the cell culture market in the coming years.

By application, the biopharmaceutical production segment accounted for the largest share of the market in 2025.
In 2025, the biopharmaceutical production segment accounted for the largest share of the application segment in the global cell culture market. The biopharmaceutical production segment is further categorized into vaccine production, monoclonal antibody production, and other therapeutic protein production. The growing prevalence of infectious diseases is boosting demand for biopharmaceuticals such as vaccines, monoclonal antibodies, and therapeutic proteins, thereby promoting the growth of biopharmaceutical production in the cell culture market.

The sera, media, and reagents segment accounted for a major share of the consumables market in 2025.
The cell culture consumables market is categorized by type into sera, media, and reagents; vessels; and accessories. The sera, media, and reagents segment accounted for the largest share of the cell culture consumables market in 2025. The large share of this segment is attributed to repeated bulk purchases and the need for consumables in the biotechnology and pharmaceutical industries. Research labs and production facilities often require large quantities of sera, media, reagents, vessels, and accessories to sustain continuous cell culture activities. This leads to frequent and substantial procurement for experimentation, testing, and manufacturing processes.

The Asia Pacific region is expected to experience the highest CAGR in the cell culture market from 2026 to 2031.
The cell culture market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding biologics and biosimilar manufacturing, rising vaccine production, increasing cell & gene therapy activity, and growing government support for domestic biomanufacturing. Countries such as China, India, Japan, South Korea, and Australia are strengthening their cell culture capabilities through investments in biopharmaceutical production, regenerative medicine, stem cell research, and advanced bioprocessing infrastructure. The region is also benefiting from growing CDMO activity, cost-efficient manufacturing, rising clinical research, and wider adoption of serum-free media, single-use systems, culture vessels, reagents, and other cell culture consumables.

The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side (70%) and Demand Side (30%)
・By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
・By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Plant Cell Technology Inc. (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US) are some of the key companies offering cell culture solutions.

Research Coverage
This research report categorizes the cell culture market by product [consumables (sera, media, reagents; vessels, and other consumables & accessories), equipment (supporting equipment, bioreactors, and storage equipment)], application [biopharmaceutical production (monoclonal antibody production, vaccine production, and other therapeutic protein production), diagnostics, tissue engineering & regenerative medicine (cell & gene therapy and other tissue engineering & regenerative medicine applications), drug screening & development, and other applications], end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the cell culture market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the cell culture market.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the cell culture market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies
The report provides insights on the following pointers:
・Analysis of key drivers (increasing support and funding for cell-based research, rising demand for serum-free and animal component-free media, growing popularity of monoclonal antibodies and biosimilars, increasing adoption of single-use technologies, and growth in advanced therapy medicinal products), restraints (high cost of cell biology research and limitations in producing high-density cell cultures), opportunities (growing opportunities in emerging economies, rising demand for 3D cell culture, and Increasing focus on next-generation therapeutics), and challenges (ethical concern regarding cell usage, and disposal of plastic consumables) influencing the growth of the market.
・Product Development/Innovation: Detailed insights on newly launched products of the cell culture market
・Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell culture market
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Caisson Labs (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US).
The report also helps stakeholders understand trends in the cell culture market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the cell culture sector.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.2.1 INCLUSIONS & EXCLUSIONS 61
1.3 STUDY SCOPE 61
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 62
1.3.2 YEARS CONSIDERED 63
1.3.3 CURRENCY CONSIDERED 64
1.3.4 UNIT CONSIDERED 64
1.4 STAKEHOLDERS 64
1.5 SUMMARY OF CHANGES 64
2 EXECUTIVE SUMMARY 66
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 66
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 68
2.3 DISRUPTIVE TRENDS IN CELL CULTURE MARKET 69
2.4 HIGH-GROWTH SEGMENTS 70
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 71
3 PREMIUM INSIGHTS 72
3.1 CELL CULTURE MARKET OVERVIEW 72
3.2 NORTH AMERICA: CELL CULTURE MARKET, BY CONSUMABLE AND COUNTRY 73
3.3 CELL CULTURE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
3.4 CELL CULTURE MARKET SHARE, BY END USER 74
4 MARKET OVERVIEW 75
4.1 INTRODUCTION 75
4.2 MARKET DYNAMICS 75
4.2.1 DRIVERS 76
4.2.1.1 Increasing support and funding for cell-based research 76
4.2.1.2 Rising demand for serum-free and animal component-free media 78
4.2.1.3 Growing popularity of monoclonal antibodies and biosimilars 79
4.2.1.4 Increasing adoption of single-use technologies 82
4.2.1.5 Growth in advanced therapy medicinal products 82
4.2.2 RESTRAINTS 84
4.2.2.1 High cost of cell biology research 84
4.2.2.2 Limitations in producing high-density cell cultures 84
 
4.2.3 OPPORTUNITIES 85
4.2.3.1 Rising demand for 3D cell culture 85
4.2.3.2 Growth opportunities in emerging economies 86
4.2.3.3 Increasing focus on next-generation therapeutics 87
4.2.4 CHALLENGES 88
4.2.4.1 Disposal of plastic consumables 88
4.2.4.2 Ethical concerns related to cell usage 89
4.3 UNMET NEEDS & WHITE SPACES 90
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 90
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 91
5 INDUSTRY TRENDS 92
5.1 PORTER’S FIVE FORCES ANALYSIS 92
5.1.1 BARGAINING POWER OF SUPPLIERS 93
5.1.2 BARGAINING POWER OF BUYERS 93
5.1.3 THREAT OF NEW ENTRANTS 93
5.1.4 THREAT OF SUBSTITUTES 93
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.2 MACROECONOMIC OUTLOOK 93
5.2.1 INTRODUCTION 93
5.2.2 GDP TRENDS & FORECAST 94
5.2.3 TRENDS IN GLOBAL CELL CULTURE INDUSTRY 94
5.3 VALUE CHAIN ANALYSIS 95
5.4 ECOSYSTEM ANALYSIS 96
5.5 PRICING ANALYSIS 99
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 99
5.5.2 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS, BY REGION 101
5.6 TRADE ANALYSIS 102
5.6.1 IMPORT SCENARIO (HS CODE 382100) 103
5.6.2 EXPORT SCENARIO (HS CODE 382100) 104
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 105
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 106
5.9 INVESTMENT AND FUNDING SCENARIO 107
5.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 108
5.10 IMPACT OF 2025 US TARIFFS ON CELL CULTURE MARKET 109
5.10.1 INTRODUCTION 109
5.10.2 KEY TARIFF RATES 109
5.10.3 PRICE IMPACT ANALYSIS 110
5.10.4 IMPACT ON COUNTRY/REGION 111
5.10.4.1 US 111
5.10.4.2 Europe 111
5.10.4.3 Asia Pacific 112
5.10.5 IMPACT ON END-USE INDUSTRIES 112
5.10.5.1 Pharmaceutical & biotech companies 112
5.10.5.2 Hospitals & diagnostic laboratories 113
5.10.5.3 Academic & research institutes 113
5.10.5.4 Contract research organizations & contract development and manufacturing organizations 113
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 114
6.1 TECHNOLOGY ANALYSIS 114
6.1.1 KEY EMERGING TECHNOLOGIES 114
6.1.1.1 Single-use technology 114
6.1.1.2 Flow cytometry 116
6.1.1.3 Microscopy 116
6.1.2 COMPLEMENTARY TECHNOLOGIES 116
6.1.2.1 High-throughput screening 116
6.1.2.2 Mass spectrometry 116
6.1.3 ADJACENT TECHNOLOGIES 117
6.1.3.1 Microfluidics and organ-on-a-chip 117
6.1.3.2 3D bioprinting 117
6.2 TECHNOLOGY/PRODUCT ROADMAP 118
6.3 PATENT ANALYSIS 118
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL CULTURE PATENTS 119
6.4 FUTURE APPLICATIONS 121
6.5 IMPACT OF AI/GEN AI ON CELL CULTURE MARKET 122
6.5.1 BEST PRACTICES IN CELL CULTURE WORKFLOW 123
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL CULTURE MARKET 124
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 124
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL CULTURE MARKET 124
7 SUSTAINABILITY & REGULATORY LANDSCAPE 126
7.1 REGIONAL REGULATIONS & COMPLIANCE 126
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
7.1.2 REGULATORY FRAMEWORK 129
7.1.2.1 North America 129
7.1.2.2 Europe 129
7.1.2.3 Asia Pacific 130
7.1.2.4 Latin America 131
7.1.2.5 Middle East & Africa 131
7.1.3 INDUSTRY STANDARDS 131
 
7.2 SUSTAINABILITY INITIATIVES 132
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 132
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 133
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 134
8.1 DECISION-MAKING PROCESS 134
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 134
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 134
8.2.2 KEY BUYING CRITERIA, BY END USER 135
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 137
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 137
8.5 MARKET PROFITABILITY 137
9 CELL CULTURE MARKET, BY PRODUCT 138
9.1 INTRODUCTION 139
9.2 CONSUMABLES 139
9.2.1 SERA, MEDIA, AND REAGENTS 143
9.2.1.1 Media 147
9.2.1.1.1 Serum-free media 151
9.2.1.1.1.1 CHO media 156
9.2.1.1.1.1.1 High-yield biologics manufacturing to sustain demand for optimized CHO serum-free media 156
9.2.1.1.1.2 HEK 293 media 159
9.2.1.1.1.2.1 Viral vector manufacturing and transient expression workflows to accelerate HEK 293 media adoption 159
9.2.1.1.1.3 Serum-free stem cell media 163
9.2.1.1.1.3.1 Regenerative medicine, iPSC models, and cell therapy translation to drive specialized stem cell media demand 163
9.2.1.1.1.4 Vero Cell media 166
9.2.1.1.1.4.1 Increasing vaccine manufacturing to support demand for serum-free Vero cell media 166
9.2.1.1.1.5 BHK media 170
9.2.1.1.1.5.1 Vaccine production and viral vector workflows to support demand for BHK serum-free media 170
9.2.1.1.1.6 Other serum-free media 173
9.2.1.1.2 Classical media & salts 176
9.2.1.1.2.1 Standardized basal media and salt solutions to support routine culture, assay reproducibility, and vaccine production 176
9.2.1.1.3 Stem cell culture media 180
9.2.1.1.3.1 Rising use of stem cell models and regenerative medicine workflows to drive demand for specialized culture media 180
 
9.2.1.1.4 Chemically-defined media 183
9.2.1.1.4.1 Increasing need for reproducible, animal component-free workflows to support biologics and advanced therapy development 183
9.2.1.1.5 Specialty media 187
9.2.1.1.5.1 Suitability for use in selective cell types in bioprocessing and biomanufacturing industries to boost market 187
9.2.1.1.6 Other media 191
9.2.1.2 Reagents 195
9.2.1.2.1 Growth factors 199
9.2.1.2.1.1 Need to regulate cell proliferation, differentiation, and migration to sustain growth 199
9.2.1.2.2 Supplements 202
9.2.1.2.2.1 Need to improve cell growth, nutrient availability, and bioproduction performance to support segment growth 202
9.2.1.2.3 Buffers & chemicals 206
9.2.1.2.3.1 Ability to maintain stable pH levels to facilitate growth 206
9.2.1.2.4 Cell dissociation reagents 209
9.2.1.2.4.1 Ability to minimize cell stress and reduce cell damage to foster growth 209
9.2.1.2.5 Balanced salt solutions 213
9.2.1.2.5.1 Ability to maintain optimal physiological conditions for cell growth and experimentation to assist growth 213
9.2.1.2.6 Attachment & matrix factors 216
9.2.1.2.6.1 Rising adoption of 3D cell culture models to support growth 216
9.2.1.2.7 Antibiotics/Antimycotics 220
9.2.1.2.7.1 Ability to mitigate growth of contaminating bacteria, fungi, and mycoplasma to drive market 220
9.2.1.2.8 Cryoprotective reagents 223
9.2.1.2.8.1 Ability to preserve cell viability during freezing and thawing to aid growth 223
9.2.1.2.9 Contamination detection kits 226
9.2.1.2.9.1 Need for rapid identification of microbial contaminants to promote growth 226
9.2.1.2.10 Other reagents 230
9.2.1.3 Sera 233
9.2.1.3.1 Fetal bovine sera 236
9.2.1.3.1.1 Increasing role of fetal bovine sera in cell proliferation to favor growth 236
9.2.1.3.2 Adult bovine sera 240
9.2.1.3.2.1 Cost-effectiveness to contribute to growth 240
9.2.1.3.3 Other animal sera 243
 
9.2.2 VESSELS 247
9.2.2.1 Cell factory systems/cell stacks 250
9.2.2.1.1 Efficient and scalable solutions for large-scale expansion to drive adoption 250
9.2.2.2 Roller/roux bottles 254
9.2.2.2.1 Scalability, cost-effectiveness, and ease of handling to support growth 254
9.2.2.3 Flasks 257
9.2.2.3.1 Growing advancements in cell culture flasks to boost market 257
9.2.2.4 Multiwell plates 261
9.2.2.4.1 Increasing adoption of multiwell plates in high-throughput or high-content screening to aid growth 261
9.2.2.5 Petri dishes 264
9.2.2.5.1 Rising use of petri dishes as sterile containers to sustain growth 264
9.2.3 OTHER CONSUMABLES & ACCESSORIES 267
9.2.3.1 Reduced preparation time and equipment performance improvements to augment growth 267
9.3 EQUIPMENT 270
9.3.1 SUPPORTING EQUIPMENT 274
9.3.1.1 Filtration systems 277
9.3.1.1.1 Sterile filtration for contamination-controlled workflows to boost market 277
9.3.1.2 Cell counters 281
9.3.1.2.1 Growing adoption of automated cell counters to propel market 281
9.3.1.3 Carbon dioxide incubators 285
9.3.1.3.1 Increasing focus of research institutes on developing lab-scale incubators to drive market 285
9.3.1.4 Centrifuges 289
9.3.1.4.1 Increasing demand for bioproduction applications to drive adoption of centrifuges 289
9.3.1.5 Autoclaves 293
9.3.1.5.1 Reliance on single-use labware and equipment to affect demand for autoclaves 293
9.3.1.6 Microscopes 296
9.3.1.6.1 Rising adoption of live-cell imaging in 3D culture and stem cell models to support segment growth 296
9.3.1.7 Biosafety cabinets 300
9.3.1.7.1 Rising focus on contamination control and operator safety to support segment growth 300
9.3.1.8 Other supporting equipment 304
 
9.3.2 BIOREACTORS 307
9.3.2.1 Rising biologics and advanced therapy production to accelerate adoption of scalable bioreactor systems 307
9.3.3 STORAGE EQUIPMENT 311
9.3.3.1 Refrigerators & freezers 315
9.3.3.1.1 Increasing need for storage solutions to propel market 315
9.3.3.2 Cryostorage systems 318
9.3.3.2.1 Benefits of long-term preservation of cell cultures to support growth 318
10 CELL CULTURE MARKET, BY APPLICATION 322
10.1 INTRODUCTION 323
10.2 BIOPHARMACEUTICAL PRODUCTION 323
10.2.1 MONOCLONAL ANTIBODY PRODUCTION 327
10.2.1.1 Increasing approval and launch of monoclonal antibodies to amplify growth 327
10.2.2 VACCINE PRODUCTION 331
10.2.2.1 Rising incidence of infectious diseases to support growth 331
10.2.3 OTHER THERAPEUTIC PROTEIN PRODUCTION 335
10.3 DIAGNOSTICS 338
10.3.1 USE OF CULTURED CELLS IN CYTOGENETICS AND ASSAY VALIDATION TO SUPPORT SEGMENT GROWTH 338
10.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE 342
10.4.1 CELL & GENE THERAPY 346
10.4.1.1 Rising approvals and manufacturing investments in advanced therapies to propel segment growth 346
10.4.2 OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS 350
10.5 DRUG SCREENING & DEVELOPMENT 353
10.5.1 ADOPTION OF HUMAN-RELEVANT 3D MODELS AND AUTOMATED SCREENING PLATFORMS TO PROPEL SEGMENT GROWTH 353
10.6 OTHER APPLICATIONS 357
11 CELL CULTURE MARKET, BY END USER 360
11.1 INTRODUCTION 361
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 361
11.2.1 INCREASING DEMAND FOR CULTURE CELL LINES FOR DRUG SCREENING AND R&D TO AID GROWTH 361
11.3 HOSPITALS & DIAGNOSTIC LABORATORIES 365
11.3.1 GROWING USE OF CELL CULTURE FOR CELLULAR PHYSIOLOGY, DISEASE MECHANISMS, AND DRUG RESPONSES TO BOOST MARKET 365
11.4 ACADEMIC & RESEARCH INSTITUTES 369
11.4.1 RISING FUNDING ACTIVITIES TO CONTRIBUTE TO GROWTH 369
11.5 OTHER END USERS 372
 
12 CELL CULTURE MARKET, BY REGION 376
12.1 INTRODUCTION 377
12.2 NORTH AMERICA 377
12.2.1 US 385
12.2.1.1 Strong biologics pipeline and domestic cell therapy manufacturing investments to bolster growth 385
12.2.2 CANADA 392
12.2.2.1 Increasing funding and investments for cell-based therapies to boost market 392
12.3 EUROPE 399
12.3.1 GERMANY 406
12.3.1.1 Biologics manufacturing strength and mRNA oncology investments to drive demand 406
12.3.2 UK 412
12.3.2.1 ATMP clinical infrastructure and government life sciences strategy to boost growth 412
12.3.3 FRANCE 418
12.3.3.1 Rising number of cell-based research projects to enhance growth 418
12.3.4 ITALY 424
12.3.4.1 Strong government support for R&D activities to spur growth 424
12.3.5 SPAIN 430
12.3.5.1 Rising biotechnology R&D investment to support cell-based research applications 430
12.3.6 REST OF EUROPE 436
12.4 ASIA PACIFIC 442
12.4.1 CHINA 450
12.4.1.1 Large-scale CRDMO activity and multinational cell therapy investments to accelerate growth 450
12.4.2 JAPAN 457
12.4.2.1 Rising government initiatives and increasing investments in biotech to intensify growth 457
12.4.3 INDIA 463
12.4.3.1 Favorable government support and expansion by key cell culture players to augment growth 463
12.4.4 SOUTH KOREA 469
12.4.4.1 Growing pharmaceutical sector to drive market 469
12.4.5 AUSTRALIA 475
12.4.5.1 Regenerative medicine funding and hospital-linked CAR-T manufacturing to support growth 475
12.4.6 REST OF ASIA PACIFIC 481
 
12.5 LATIN AMERICA 488
12.5.1 BRAZIL 495
12.5.1.1 Cell therapy partnerships and vaccine manufacturing capacity to strengthen regional leadership 495
12.5.2 MEXICO 501
12.5.2.1 Pharmaceutical manufacturing investments and clinical research capacity to support steady growth 501
12.5.3 REST OF LATIN AMERICA 507
12.6 MIDDLE EAST 514
12.6.1 GCC COUNTRIES 521
12.6.1.1 Saudi Arabia 527
12.6.1.1.1 Increasing focus on expansion to drive market 527
12.6.1.2 UAE 533
12.6.1.2.1 Increasing shift from importing to manufacturing pharmaceuticals to boost market 533
12.6.1.3 Rest of GCC Countries 539
12.6.2 REST OF MIDDLE EAST 545
12.7 AFRICA 551
12.7.1 RISING GRANTS AND FUNDING FOR CELL AND GENE THERAPY PRODUCTS TO FOSTER GROWTH 551
13 COMPETITIVE LANDSCAPE 558
13.1 OVERVIEW 558
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 558
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL CULTURE MARKET 558
13.3 REVENUE ANALYSIS, 2021–2025 560
13.4 MARKET SHARE ANALYSIS, 2025 561
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 563
13.5.1 STARS 564
13.5.2 EMERGING LEADERS 564
13.5.3 PERVASIVE PLAYERS 564
13.5.4 PARTICIPANTS 564
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 566
13.5.5.1 Company footprint 566
13.5.5.2 Regional footprint 566
13.5.5.3 Product footprint 567
13.5.5.4 Application footprint 568
13.5.5.5 End-user footprint 569
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 570
13.6.1 PROGRESSIVE COMPANIES 570
13.6.2 RESPONSIVE COMPANIES 570
13.6.3 DYNAMIC COMPANIES 570
13.6.4 STARTING BLOCKS 570
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 571
13.6.5.1 Detailed list of key startups/SMEs 571
13.6.5.2 Competitive benchmarking of key startups/SMEs 572
13.7 COMPANY VALUATION AND FINANCIAL METRICS 573
13.7.1 FINANCIAL METRICS 573
13.7.2 COMPANY VALUATION 573
13.8 BRAND/PRODUCT COMPARISON 574
13.9 COMPETITIVE SCENARIO 574
13.9.1 PRODUCT LAUNCHES 574
13.9.2 DEALS 575
13.9.3 EXPANSIONS 576
14 COMPANY PROFILES 578
14.1 INTRODUCTION 578
14.2 KEY PLAYERS 578
14.2.1 THERMO FISHER SCIENTIFIC INC. 578
14.2.1.1 Business overview 578
14.2.1.2 Products offered 579
14.2.1.3 Recent developments 592
14.2.1.3.1 Product launches 592
14.2.1.3.2 Deals 594
14.2.1.3.3 Expansions 595
14.2.1.4 MnM view 596
14.2.1.4.1 Right to win 596
14.2.1.4.2 Strategic choices 596
14.2.1.4.3 Weaknesses and competitive threats 596
14.2.2 DANAHER CORPORATION 597
14.2.2.1 Business overview 597
14.2.2.2 Products offered 598
14.2.2.3 Recent developments 608
14.2.2.3.1 Product launches 608
14.2.2.3.2 Deals 609
14.2.2.3.3 Expansions 610
14.2.2.3.4 Other developments 611
14.2.2.4 MnM view 611
14.2.2.4.1 Right to win 611
14.2.2.4.2 Strategic choices 612
14.2.2.4.3 Weaknesses and competitive threats 612
 
14.2.3 MERCK KGAA 613
14.2.3.1 Business overview 613
14.2.3.2 Products offered 614
14.2.3.3 Recent developments 621
14.2.3.3.1 Product launches 621
14.2.3.3.2 Deals 621
14.2.3.3.3 Expansions 622
14.2.3.4 MnM view 624
14.2.3.4.1 Right to win 624
14.2.3.4.2 Strategic choices 624
14.2.3.4.3 Weaknesses and competitive threats 624
14.2.4 SARTORIUS AG 625
14.2.4.1 Business overview 625
14.2.4.2 Products offered 626
14.2.4.3 Recent developments 634
14.2.4.3.1 Product launches 634
14.2.4.3.2 Deals 635
14.2.4.3.3 Expansions 637
14.2.4.4 MnM view 638
14.2.4.4.1 Right to win 638
14.2.4.4.2 Strategic choices 638
14.2.4.4.3 Weaknesses and competitive threats 639
14.2.5 CORNING INCORPORATED 640
14.2.5.1 Business overview 640
14.2.5.2 Products offered 641
14.2.5.3 Recent developments 650
14.2.5.3.1 Deals 650
14.2.6 FUJIFILM HOLDINGS CORPORATION 652
14.2.6.1 Business overview 652
14.2.6.2 Products offered 653
14.2.6.3 Recent developments 659
14.2.6.3.1 Product launches 659
14.2.6.3.2 Deals 660
14.2.6.3.3 Other developments 660
14.2.7 BD 661
14.2.7.1 Business overview 661
14.2.7.2 Product offered 662
14.2.7.3 Recent developments 664
14.2.7.3.1 Product Launches 664
14.2.7.3.2 Deals 664
14.2.7.3.3 Other developments 665
 
14.2.8 EPPENDORF SE 666
14.2.8.1 Business overview 666
14.2.8.2 Products offered 667
14.2.8.3 Recent developments 672
14.2.8.3.1 Product launches 672
14.2.8.3.2 Expansions 673
14.2.9 LONZA 674
14.2.9.1 Business overview 674
14.2.9.2 Products offered 675
14.2.9.3 Recent developments 678
14.2.9.3.1 Product launches 678
14.2.9.3.2 Deals 678
14.2.10 GETINGE 679
14.2.10.1 Business overview 679
14.2.10.2 Products offered 680
14.2.10.3 Recent developments 681
14.2.10.3.1 Product launches 681
14.2.10.3.2 Deals 682
14.2.11 AGILENT TECHNOLOGIES, INC. 683
14.2.11.1 Business overview 683
14.2.11.2 Products offered 684
14.2.11.3 Recent developments 686
14.2.11.3.1 Product launches 686
14.2.11.3.2 Deals 687
14.2.11.3.3 Expansions 687
14.2.12 HIMEDIA LABORATORIES 688
14.2.12.1 Business overview 688
14.2.12.2 Products offered 688
14.2.13 BIO-TECHNE 692
14.2.13.1 Business overview 692
14.2.13.2 Products offered 693
14.2.13.3 Recent developments 697
14.2.13.3.1 Product launches 697
14.2.13.3.2 Deals 697
14.2.13.3.3 Expansions 698
14.3 OTHER PLAYERS 699
14.3.1 MILTENYI BIOTEC 699
14.3.2 STEMCELL TECHNOLOGIES 701
14.3.3 SOLIDA BIOTECH GMBH 704
14.3.4 CAISSON LABS 705
14.3.5 PROMOCELL GMBH 706
14.3.6 INVIVOGEN 707
14.3.7 PAN-BIOTECH 708
14.3.8 CELLEXUS 709
14.3.9 MEISSNER FILTRATION PRODUCTS, INC. 710
14.3.10 ADOLF KÜHNER AG 712
14.3.11 ADVANCION CORPORATION 713
14.3.12 BIOSPHERIX LLC 714
15 RESEARCH METHODOLOGY 715
15.1 RESEARCH DATA 715
15.1.1 SECONDARY DATA 716
15.1.1.1 Key secondary sources 716
15.1.1.2 Key data from secondary research 716
15.1.2 PRIMARY DATA 717
15.1.2.1 Key primary participants 717
15.1.2.2 Breakdown of primary interviews 717
15.1.2.3 Key data from primary sources 717
15.2 MARKET SIZE ESTIMATION 718
15.2.1 GLOBAL CELL CULTURE MARKET ESTIMATION, 2025 718
15.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up) 718
15.2.1.2 Approach 2: Primary research 720
15.2.1.2.1 Key industry insights 720
15.2.1.3 Approach 3: MnM repository analysis 720
15.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 721
15.3 MARKET GROWTH RATE PROJECTIONS 722
15.4 DATA TRIANGULATION 724
15.5 RESEARCH ASSUMPTIONS 725
15.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT 726
16 APPENDIX 727
16.1 DISCUSSION GUIDE 727
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 731
16.3 CUSTOMIZATION OPTIONS 733
16.4 RELATED REPORTS 733
16.5 AUTHOR DETAILS 735